Localized striatal delivery of GDNF as a treatment for Parkinson disease

Nature Neuroscience

Volumn 7, Issue 2, 2004, Pages 105-110

  Kirik, Deniz ^a   Georgievska, Biljana ^a   Björklund, Anders ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; ADENOVIRUS VECTOR; AMPHETAMINE; DOPA; FLUORINE 18; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LENTIVIRUS VECTOR; OXIDOPAMINE; PARVOVIRUS VECTOR; TYROSINE 3 MONOOXYGENASE; VOLTAGE GATED CALCIUM CHANNEL;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD BRAIN BARRIER; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; GENE TRANSFER; GLOBUS PALLIDUS; HUMAN; MONKEY; NERVE FIBER REGENERATION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OPEN STUDY; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; REVIEW;

ANIMALS; CORPUS STRIATUM; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; INJECTIONS, INTRAVENTRICULAR; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RECOVERY OF FUNCTION;

EID: 1642499508     PISSN: 10976256     EISSN: None     Source Type: Journal    
DOI: 10.1038/nn1175     Document Type: Review

References (49)

1. Tuszynski, M.H. Growth-factor gene therapy for neurodegenerative disorders. Lancet Neurol. 1, 51-57 (2002).
2. Aebischer, P. & Ridet, J. Recombinant proteins for neurodegenerative diseases: the delivery issue. Trends Neurosci. 24, 533-540 (2001).
3. Gill, S.S. et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9, 589-595 (2003).
4. Kearns, C.M., Cass, W.A., Smoot, K., Kryscio, R. & Gash, D.M. GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis. J. Neurosci. 17, 7111-7118 (1997).
5. Sullivan, A.M., Opacka-Juffry, J. & Blunt, S.B. Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo. Eur. J. Neurosci. 10, 57-63 (1998).
6. Sauer, H., Rosenblad, C. & Bjorklund, A. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc. Natl. Acad. Sci. USA 92, 8935-8939 (1995).
7. Kirik, D., Rosenblad, C. & Bjorklund, A. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur. J. Neurosci. 12, 3871-3882 (2000).
8. Winkler, C., Sauer, H., Lee, C.S. & Bjorklund, A. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 16, 7206-7215 (1996).
9. Sauer, H. & Oertel, W.H. Progressive degeneration of nigrostriatal dopamine neurons following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat. Neuroscience 59, 401-415 (1994).
10. Rosenblad, C., Kirik, D. & Bjorklund, A. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Exp. Neurol. 161, 503-516 (2000).
11. Rosenblad, C. et al. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur. J. Neurosci. 11, 1554-1566 (1999).
12. Kimpinski, K., Campenot, R.B. & Mearow, K. Effects of the neurotrophins nerve growth factor, neurotrophin-3, and brain-derived neurotrophic factor (BDNF) on neurite growth from adult sensory neurons in compartmented cultures. J. Neurobiol. 33, 395-410 (1997).
13. Hudson, J. et al. Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res. Bull. 36, 425-432 (1995).
14. Gash, D.M. et al. Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys. J. Comp. Neurol. 363, 345-358 (1995).
15. Hebert, M.A., Van Horne, C.G., Hoffer, B.J. & Gerhardt, G.A. Functional effects of GDNF in normal rat striatum: presynaptic studies using in vivo electrochemistry and microdialysis. J. Pharmacol. Exp. Ther. 279, 1181-1190 (1996).
16. Martin, D. et al. Intranigral or intrastriatal injections of GDNF: effects on monoamine levels and behavior in rats. Eur. J. Pharmacol. 317, 247-256 (1996).
17. Hebert, M.A. & Gerhardt, G.A. Behavioral and neurochemical effects of intranigral administration of glial cell line-derived neurotrophic factor on aged Fischer 344 rats. J. Pharmacol. Exp. Ther. 282, 760-768 (1997).
18. Horger, B.A. et al. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J. Neurosci. 18, 4929-4937 (1998).
19. Martin, D. et al. Glial cell line-derived neurotrophic factor: the lateral cerebral ventricle as a site of administration for stimulation of the substantia nigra dopamine system in rats. Eur. J. Neurosci. 8, 1249-1255 (1996).
20. Kobayashi, S., Ogren, S.O., Hoffer, B.J. & Olson, L. Dopamine D1 and D2 receptor-mediated acute and long-lasting behavioral effects of glial cell line-derived neurotrophic factor administered into the striatum. Exp. Neurol. 154, 302-314 (1998).
21. Maswood, N. et al. Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys. Neurobiol. Aging 23, 881-889 (2002).
22. Grondin, R. et al. Glial cell line-derived neurotrophic factor increases stimulus-evoked dopamine release and motor speed in aged rhesus monkeys. J. Neurosci. 23, 1974-1980 (2003).
23. Ai, Y. et al. Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J. Comp. Neurol. 461, 250-261 (2003).
24. Gash, D.M. et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380, 252-255 (1996).
25. Zhang, Z. et al. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J. Pharmacol. Exp. Ther 282, 1396-1401 (1997).
26. Miyoshi, Y. et al. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys. Ann. Neurol. 42, 208-214 (1997).
27. Gerhardt, G.A. et al. GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys. Brain Res. 817, 163-171 (1999).
28. Costa, S., Iravani, M.M., Pearce, R.K. & Jenner, P. Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets. Eur. J. Pharmacol. 412, 45-50 (2001).
29. Grondin, R. et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125, 2191-2201 (2002).
30. Hoffer, B.J. et al. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci. Lett. 182, 107-111 (1994).
31. Hoffman, A.F., van Horne, C.G., Eken, S., Hoffer, B.J. & Gerhardt, G.A. In vivo microdialysis studies on somatodendritic dopamine release in the rat substantia nigra: effects of unilateral 6-OHDA lesions and GDNF. Exp. Neurol. 147, 130-141 (1997).
32. Lapchak, P.A., Miller, P.J., Collins, F. & Jiao, S. Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intra-ventricular and intranigral delivery. Neuroscience 78, 61-72 (1997).
33. Kirik, D., Georgievska, B., Rosenblad, C. & Bjorklund, A. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. Eur. J. Neurosci. 13, 1589-1599 (2001).
34. Pothos, E.N. et al. Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size. J. Neurosci. 20, 7297-7306 (2000).
35. + channels in midbrain dopaminergic neurons. Nat. Neurosci. 4, 1071-1078 (2001).
36. 2+ channels and excitatory synaptic transmission in midbrain dopaminergic neurons. Neurosignals 12, 78-88 (2003).
37. Rosenblad, C., Martinez-Serrano, A. & Bjorklund, A. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience 82, 129-137 (1998).
38. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N. Engl. J. Med. 345, 956-963 (2001).
39. Choi-Lundberg, D.L. et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy [see comments]. Science 275, 838-841 (1997).
40. Connor, B. et al. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Ther. 6, 1936-1951 (1999).
41. Mandel, R.J., Spratt, S.K., Snyder, R.O. & Leff, S.E. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc. Natl. Acad. Sci. USA 94, 14083-14088 (1997).
42. Kirik, D., Rosenblad, C., Bjorklund, A. & Mandel, R.J. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J. Neurosci. 20, 4686-4700 (2000).
43. Deglon, N. et al. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum. Gene Ther. 11, 179-190 (2000).
44. Bensadoun, J.C. et al. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Exp. Neurol. 164, 15-24 (2000).
45. Kordower, J.H. et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767-773 (2000).
46. Georgievska, B., Kirik, D. & Bjorklund, A. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp. Neurol. 177, 461-474 (2002).
47. Bjorklund, A. et al. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res. 886, 82-98 (2000).
48. Nutt, J.G. et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60, 69-73 (2003).
49. Iravani, M. et al. GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets. Eur. J. Neurosci. 13, 597-608 (2001).